Prolia (Denosumab) Medicaid Coverage by State Tier

Why Medicaid Coverage for Prolia Is More Complex Than Standard Drug Benefits

Prolia does not fit neatly into a standard pharmacy-benefit tier. Because the drug is administered by a clinician every six months, most state Medicaid programs classify it as a medical benefit, billing under a J-code (J0897) rather than processing it through a retail pharmacy. That single fact drives most of the access friction patients encounter.

Medical Benefit vs. Pharmacy Benefit

When Prolia is billed as a medical benefit, the administering provider (usually a physician's office, infusion center, or FQHC) must obtain prior authorization from the state Medicaid fee-for-service program or the patient's managed-care organization before injecting the drug. The PA criteria are set at the MCO level, so two patients in the same state but enrolled in different Medicaid managed-care plans may face different step-therapy requirements.

Some Medicaid managed-care plans in states such as California (Medi-Cal), New York (CDPAP/Medicaid Managed Care), and Texas (STAR program) have moved denosumab onto a specialty-drug formulary list that requires dispensing through a specialty pharmacy, which shifts the billing back to a pharmacy benefit. In those cases, the drug arrives at the provider's office as a patient-owned supply, and the J-code route is not used.

J-Code Reimbursement and Provider Buy-and-Bill

Under buy-and-bill, a provider purchases Prolia directly and seeks reimbursement after administration. Medicaid fee-for-service rates for J0897 are set by each state and are typically calculated as a percentage of the drug's average acquisition cost (AAC) or average manufacturer price (AMP). The CMS Medicaid Drug Rebate Program requires manufacturers to report AMP quarterly, and state payments must not exceed the federal upper limit.

Low reimbursement rates sometimes cause small practices to decline Medicaid buy-and-bill for Prolia entirely, directing patients to hospital outpatient departments where overhead reimbursement is higher. If your provider says "we don't stock Prolia for Medicaid patients," that is usually the reason.

State-by-State Coverage Tier Overview

Because Medicaid is jointly funded and individually administered, each of the 50 states plus D.C. Sets its own coverage policies. The table below groups states into three access tiers based on the combination of formulary placement, PA burden, and step-therapy requirements as of early 2026. Tier designations can change when MCO contracts are renegotiated, typically on January 1 or July 1 of each plan year.

Tier 1: Covered with Standard PA (Lower Barrier)

These states cover denosumab under Medicaid fee-for-service or through managed-care contracts with a single-level PA requiring documentation of a confirmed osteoporosis diagnosis (typically a DXA T-score at or below -2.5) and at least one documented fragility fracture or high FRAX score.

States generally in Tier 1 as of 2026: California (Medi-Cal), New York, Illinois, Michigan, Pennsylvania, Ohio, North Carolina, Georgia, Washington, Colorado, Minnesota, Oregon, Maryland, Virginia, New Jersey, Massachusetts, Connecticut.

Key documentation usually needed:

• DXA scan report showing T-score
• ICD-10 code M81.0 (age-related osteoporosis without current pathological fracture) or M80.xx (with fracture)
• Prescriber attestation that bisphosphonate therapy is contraindicated or has failed (in most plans)

Tier 2: Covered with Step Therapy Required (Moderate Barrier)

Tier 2 states require documented failure of, or intolerance to, at least one oral bisphosphonate (most commonly alendronate 70 mg weekly or risedronate 35 mg weekly) before Prolia will be authorized. Some plans in this tier also require a rheumatology or endocrinology consult.

States generally in Tier 2 as of 2026: Texas, Florida, Arizona, Missouri, Indiana, Tennessee, Wisconsin, Alabama, South Carolina, Louisiana, Kentucky, Oklahoma, Arkansas, Iowa, Kansas, Mississippi, Nevada, Utah.

Step therapy documentation usually needed:

• Trial of generic alendronate for a minimum of 6 to 12 months, or documented intolerance (GI adverse effects, esophageal conditions, inability to remain upright)
• Reason bisphosphonate treatment goal was not met
• Bone density change on sequential DXA

Tier 3: Non-Preferred or Requires Exception Process (Higher Barrier)

A smaller number of states either exclude denosumab from their preferred drug list or impose additional non-preferred designation requiring a formulary exception. In these states, prior authorization approval rates are lower, and the appeals process may be the primary route to access.

States sometimes in Tier 3 or requiring close monitoring as of 2026: Idaho, Wyoming, South Dakota, North Dakota, West Virginia, Montana, Alaska.

In Tier 3 states, a letter of medical necessity from a specialist (endocrinologist, rheumatologist, or orthopedist) substantially improves approval odds. The CMS model prior authorization requirements do not override state formulary decisions, so the exception process is the practical path.

Always verify current tier placement directly with the patient's MCO or fee-for-service program. Coverage policies change every plan year.

Prior Authorization: What Clinicians and Patients Need to Know

Getting PA right the first time saves weeks. Denials generate re-review cycles that delay treatment, and denosumab's every-6-month schedule means a 6-week delay is clinically meaningful.

Minimum Documentation Package for Denosumab PA

1. DXA T-score: Most plans require a score at or below -2.5 at the spine or hip, or -1.0 to -2.5 with additional risk factors per the National Osteoporosis Foundation Clinician's Guide.
2. FRAX score: A 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3%, satisfies medical necessity in most Tier 1 and Tier 2 plans.
3. Bisphosphonate trial documentation: For Tier 2 states, pharmacy records showing the fill history for alendronate or risedronate, combined with a clinical note describing the reason for discontinuation, are required.
4. Indication specificity: Prolia has separate FDA indications for postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and bone loss related to hormone ablation therapy in prostate and breast cancer. The FDA label approved in 2010 is the authoritative source Medicaid plans reference for covered indications.

What Happens After a Denial

A first-level denial is not the end. CMS regulations under 42 CFR 438.400 require Medicaid MCOs to provide an internal appeal process. If the internal appeal is denied, a patient is entitled to a state fair hearing. A peer-to-peer review between the prescribing physician and the plan's medical director resolves a meaningful proportion of denosumab denials before the formal appeal stage.

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline explicitly states that denosumab is appropriate first-line therapy when oral bisphosphonates are contraindicated or not tolerated, which gives prescribers a guideline-backed argument against mandatory step therapy.

How to Get Prolia Cheaper: Programs Outside Medicaid

Even when Medicaid covers Prolia, cost-sharing obligations can exist in some Medicaid categories (such as MAGI expansion adults in states with nominal copays). For patients who are uninsured, underinsured, or in Medicaid coverage gaps, several programs reduce the net cost substantially.

Amgen SupportPlus (Manufacturer Patient Assistance)

Amgen's SupportPlus program provides Prolia at no cost to qualifying uninsured or underinsured patients. Eligibility is income-based; in prior years, household income thresholds have been set at or below 500% of the federal poverty level. The application requires a provider attestation, proof of income, and proof of insurance status. Processing takes 2 to 4 weeks. Patients enrolled in any federal health care program (Medicare, Medicaid, TRICARE, VA) are not eligible for this program.

Amgen Copay Card (Commercial Insurance Only)

For patients with commercial insurance, Amgen offers a copay assistance card that can reduce the patient's cost to as low as $0 per injection for eligible commercially insured patients. This card cannot be used with any federal or state insurance, including Medicaid.

Biosimilar Options: Jubbonti and Wyost

In 2024, the FDA approved two denosumab biosimilars: Jubbonti (denosumab-bbdw, Sandoz) and Wyost (denosumab-bbdw, Sandoz), which are interchangeable with Prolia and Xgeva respectively. FDA biosimilar product information is available here. Biosimilar competition should reduce the wholesale acquisition cost of denosumab over the next 12 to 24 months. Some Medicaid MCOs are expected to prefer the biosimilar on their preferred drug lists by mid-2026, which may reduce PA burden for patients when the biosimilar is selected.

FQHCs and 340B Program

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities can purchase Prolia at the 340B ceiling price, which is substantially below wholesale acquisition cost. The 340B program is administered by HRSA. Patients who receive their primary care at an FQHC and who do not have Medicaid or have a Medicaid coverage gap may access denosumab through the 340B program at a drastically reduced or zero out-of-pocket cost.

Clinical Evidence Supporting Medicaid Medical Necessity Arguments

When writing letters of medical necessity or preparing for peer-to-peer reviews, citing the primary evidence base strengthens the case.

The FREEDOM Trial: Fracture Reduction Efficacy

The FREEDOM trial (N=7,868 postmenopausal women, median follow-up 3 years) compared denosumab 60 mg subcutaneous every 6 months versus placebo. Cummings et al., NEJM 2009 reported a 68% relative risk reduction in new vertebral fractures (7.2% placebo vs. 2.3% denosumab; P<0.001), a 40% reduction in hip fractures (0.7% vs. 1.2%; P<0.001), and a 20% reduction in nonvertebral fractures (8.0% vs. 6.5%; P<0.001). These are the numbers Medicaid reviewers and medical directors encounter when evaluating medical necessity.

Long-Term Extension: FREEDOM EXTEND

The FREEDOM EXTEND open-label extension followed participants for up to 10 years of continuous denosumab therapy. Bone et al., Osteoporosis International 2022 found that patients who received denosumab for the full 10 years had sustained gains in lumbar spine BMD of 21.7% from baseline, with no evidence of plateau and no new safety signals beyond what was established in FREEDOM. Continuity of therapy matters clinically: discontinuation of denosumab produces rapid bone mineral density loss and rebound vertebral fractures, making uninterrupted access particularly important.

Glucocorticoid-Induced Osteoporosis Indication

For patients on chronic glucocorticoids, the GIOP indication is important. Saag et al., Arthritis and Rheumatology 2019 (N=795) found denosumab superior to risedronate in increasing lumbar spine BMD at 24 months (+3.83% vs. +2.01%; P<0.001). This trial supports medical necessity for Medicaid patients on long-term steroid therapy who have not responded adequately to oral bisphosphonates.

Original Clinical Framework: Choosing the Right PA Pathway by Patient Profile

The following decision framework is developed from HealthRX clinical review of Medicaid PA criteria across 35 states and is intended to help prescribers select the fastest path to denosumab authorization for a given patient.

Profile A: Postmenopausal woman, T-score at or below -2.5, one or more fragility fractures, no bisphosphonate trial. Fastest path: Request PA citing the NOF Clinician's Guide recommendation for pharmacotherapy at T-score at or below -2.5. Include FRAX score. In Tier 2 states, document that fracture history itself constitutes a compelling clinical reason to bypass step therapy. Peer-to-peer review success rate is high when a fracture is documented.

Profile B: Postmenopausal woman, T-score between -1.5 and -2.5, no fracture, high FRAX score. Fastest path: Obtain a FRAX calculation showing 10-year major osteoporotic fracture probability above 20%. In Tier 1 states, this alone satisfies medical necessity. In Tier 2 states, begin alendronate 70 mg weekly and document for 3 to 6 months before requesting a denosumab PA (or document GI intolerance immediately if present).

Profile C: Patient on chronic prednisone 7.5 mg daily or higher for 3 months or more. Fastest path: Use the GIOP indication. Document the prednisone dose, duration, and T-score. Saag 2019 provides direct support for denosumab over risedronate in this population. Some Tier 2 states waive bisphosphonate step therapy for the GIOP indication.

Profile D: Male with osteoporosis or bone loss from androgen-deprivation therapy for prostate cancer. Fastest path: Reference the FDA-approved indication for male osteoporosis and the androgen-deprivation indication on the Prolia label. Many plans with step therapy for postmenopausal osteoporosis do not apply the same step therapy to ADT-related bone loss, because alendronate is not FDA-approved for that indication.

Handling Medicaid Managed Care Plan Transitions

Medicaid MCO contracts change. When a patient's MCO changes at re-enrollment, the new plan may not honor a PA granted under the prior plan. Prescribers should request a PA bridge (sometimes called a continuity-of-care exception) when a patient transitions MCOs mid-treatment. CMS requires Medicaid MCOs to provide continuity of care for at least 90 days when a patient is already established on a treatment course. Given that denosumab's dosing interval is 6 months, this 90-day bridge usually covers the next injection, but prescribers should initiate the new PA well before the bridge period expires.

HSA and FSA Eligibility for Prolia Injections

Prolia injections qualify as a medical expense under IRS Publication 502, which covers amounts paid for diagnosis, cure, mitigation, treatment, or prevention of disease. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can reimburse the cost of a Prolia injection, including the physician administration fee, when paid out-of-pocket. IRS Publication 502 is available at IRS.gov. This matters primarily for patients who have high-deductible health plans in combination with Medicaid (rare) or who lose Medicaid eligibility partway through the year and pay out-of-pocket for one injection while waiting for a new insurance plan.

What to Do If Medicaid Denies Prolia and No Alternative Programs Apply

A denial is not the final word. The structured approach below gives patients and prescribers the clearest path forward.

Step 1: Request the Denial Rationale in Writing

Medicaid MCOs must provide a written explanation of the denial under 42 CFR 438.404. The specific reason (not medically necessary, step therapy not met, non-covered service) determines the correct appeal strategy.

Step 2: File an Internal Appeal Within the Deadline

Most MCOs require internal appeals within 60 days of the denial notice. A physician letter citing the FREEDOM trial data and the Endocrine Society guideline quote below is often sufficient to overturn step-therapy denials at this stage.

The Endocrine Society 2019 guideline states: "We recommend denosumab as an alternative first-line agent for women with postmenopausal osteoporosis at high risk of fracture (Strong recommendation; Moderate quality evidence)." That language directly counters a step-therapy requirement.

Step 3: Request a Peer-to-Peer Review

A 15-minute call between the prescribing physician and the plan's medical director resolves a substantial fraction of denosumab denials before a formal state fair hearing is needed. Bring the patient's DXA report, FRAX score, fracture history, and the FREEDOM trial citation to the call.

Step 4: State Fair Hearing

If internal appeals fail, file for a state fair hearing. The patient's Medicaid rights under 42 CFR 431.220 include the right to a fair hearing. The administrative law judge at a fair hearing is not bound by the MCO's formulary policy; they apply federal and state medical necessity standards.

Step 5: Bridge with Amgen SupportPlus or 340B

While any appeal is pending, ask whether the patient qualifies for Amgen SupportPlus or whether their provider is a 340B-covered entity. These bridges prevent a dosing gap that could trigger rebound bone loss.